Lexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded to Sell by StockNews.com

StockNews.com upgraded shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) to a sell rating in a research report report published on Wednesday.

A number of other analysts have also recently commented on the stock. SVB Leerink initiated coverage on shares of Lexicon Pharmaceuticals in a research note on Tuesday. They issued an outperform rating and a $5.00 price target for the company. Needham & Company LLC reiterated a hold rating on shares of Lexicon Pharmaceuticals in a research note on Tuesday, April 23rd.

Lexicon Pharmaceuticals Stock Performance

Shares of LXRX opened at $1.65 on Wednesday. Lexicon Pharmaceuticals has a 12 month low of $0.92 and a 12 month high of $3.79. The firm has a fifty day simple moving average of $2.13 and a 200 day simple moving average of $1.74. The stock has a market capitalization of $406.30 million, a price-to-earnings ratio of -2.06 and a beta of 1.27. The company has a current ratio of 5.60, a quick ratio of 5.58 and a debt-to-equity ratio of 1.07.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.03. Lexicon Pharmaceuticals had a negative net margin of 14,573.20% and a negative return on equity of 138.54%. The business had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $0.68 million. Research analysts forecast that Lexicon Pharmaceuticals will post -0.71 EPS for the current fiscal year.

Institutional Trading of Lexicon Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Cantor Fitzgerald L. P. acquired a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter worth about $25,000. TIAA Trust National Association acquired a new stake in shares of Lexicon Pharmaceuticals during the 3rd quarter worth about $29,000. Principal Securities Inc. acquired a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter worth about $33,000. Commonwealth Equity Services LLC lifted its stake in shares of Lexicon Pharmaceuticals by 160.9% during the 3rd quarter. Commonwealth Equity Services LLC now owns 39,569 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 24,400 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Lexicon Pharmaceuticals by 350.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 28,329 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 22,043 shares during the last quarter. Institutional investors and hedge funds own 74.70% of the company’s stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.